

REMARKS

The Office Action has been carefully reviewed. No claim is allowed. Claims 5, 9, 11, 12 and 15-18 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and allowance are hereby respectfully solicited.

Claims 5, 9, 11, 12 and 15-18 have been rejected under 35 U.S.C. §112, first paragraph, for lack of enablement. The examiner states that, while the specification teaches leptin inhibiting angiogenesis in ob/ob mice, there is no guidance or any other example that leptin would inhibit angiogenesis in a normal mammal. It is the examiner's position that one of skill in the art is not enabled for inhibiting angiogenesis in mammals that are normal and not ob/ob. This rejection is respectfully traversed.

Rather than presenting arguments that would be considered by the examiner as merely attorney/agent argument, the arguments/reasoning of the applicants are presented in the form of the executed declaration attached hereto. Thus, the attached executed declaration by one of the applicants, Menachem Rubinstein, provides the arguments/reasoning that would normally be provided in this section anyways. Accordingly, this declaration in place of attorney/agent argument should be entered and fully considered as it does not raise any new issues or

Appln. No. 10/070,295
Amd. dated February 19, 2008
Reply to Office Action of April 5, 2007

require a further search. In short, from the arguments in the attached declaration, one of skill in the art would indeed be enabled for inhibiting angiogenesis in mammals as presently claimed.

Reconsideration and withdrawal of the rejection are therefore respectfully requested.

In view of the above, the claims comply with 35 U.S.C. §112 and define patentable subject matter warranting their allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By /ACY/
Allen C. Yun
Registration No. 37,971

ACY:pp
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\I\inl2\Rubinstein7\pto\2008-02-19submitDeclaration132.doc